Du har din webbläsare inställd på att inte tillåta cookies. Detta innebär att vissa funktioner på webbplatsen inte fungerar.

Gå till sidans huvudinnehåll

This page in English

Martin Gunnarsson

Befattning: Affilierad forskare Organisation: Institutionen för medicinska vetenskaper

E-post: martin.gunnarsson@oru.se

Telefon: Telefonnummer saknas

Rum: -

Forskningsämne

Medicin

Om Martin Gunnarsson

Martin Gunnarsson är docent i neurologi vid Örebro universitet kombinerat med en överläkartjänst på Universitetssjukhuset i Örebro.

Martin är utbildad vid Umeå universitet och disputerade 2001 inom ämnet immunologi med avhandlingen “The conformational complexity of alpha2-macroglobulin and its relation to multiple sclerosis”. Han tog läkarexamen 2002, erhöll läkarlegitimation 2004 och blev specialist i neurologi 2009.

Forskning

Martin Gunnarssons forskning är huvudsakligen inriktad mot neuroinflammation och olika aspekter av sjukdomen multipel skleros (MS). Från att tidigare främst ha ägnat sig åt experimentell forskning har projekten under senare år varit av klinisk eller translationell karaktär. Forskningen har bl a kretsat kring riskfaktorer, sjukdomsmekanismer och monitorering av sjukdomsaktivitet vid MS. Några projekt har också innefattat klinisk behandlingsforskning och Martin har varit prövare i ett flertal kliniska prövningar, både randomiserade och observationella. Att studera sjukdomsförloppet vid MS med olika biomarkörer och radiologiska tekniker har varit av särskilt intresse. Martin samarbetar inom MS-fältet nationellt och internationellt.

Undervisning

Martin Gunnarsson har under åren 2011-2016 ansvarat för uppbyggnaden av tema neuro-rörelse inom läkarprogrammet vid Örebro universitet. Han har haft många olika undervisningsuppdrag i läkarprogram och andra vårdprofessionsutbildningar samt verkat som examinator, och handleder aktivt studenter på forskarutbildningsnivå. Martin har också föreläst i och arrangerat olika vidareutbildningar, konferenser och symposier inom hälso- och sjukvård och var ordförande för Svensk Neurologiveckan 2016.

Samarbeten och uppdrag

Martin Gunnarsson har tidigare varit verksamhetschef för neuroverksamheter vid Universitetssjukhuset i Örebro och är numera prefekt vid Institutionen för medicinska vetenskaper, Örebro universitet. Han har varit ordförande för Svenska Neurologföreningen och ledamot i nationella programområdet för nervsystemets sjukdomar. Martin har även varit nationell SPUR-koordinator i neurologi, ledamot i AT-nämnden och Svenska MS-sällskapets styrelse samt medverkat i arbetat med Socialstyrelsens nationella riktlinjer och Läkemedelsverkets behandlingsrekommendationer vid MS. Martin är styrelseledamot i Nyckelfonden.

Forskningsprojekt
Publikationer

Pågående projekt

Monitorering av Parkinsons sjukdom på distans - Stärkande av patienternas delaktighet och förbättrad behandling med IKT-verktyg (EMPARK)

Publikationer

Artiklar i tidskrifter | Artiklar, forskningsöversikter | Konferensbidrag |

Artiklar i tidskrifter

Jons, D. , Grut, V. , Bergström, T. , Zetterberg, H. , Biström, M. , Gunnarsson, M. , Vrethem, M. , Brenner, N. & et al. (2024). Seroreactivity against lytic, latent and possible cross-reactive EBV antigens appears on average 10 years before MS induced preclinical neuroaxonal damage. Journal of Neurology, Neurosurgery and Psychiatry, 95 (4), 325-332.
Longinetti, E. , Englund, S. , Burman, J. , Fink, K. , Fogdell-Hahn, A. , Gunnarsson, M. , Hillert, J. , Langer-Gould, A. M. & et al. (2024). Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy. Journal of Neurology, Neurosurgery and Psychiatry, 95 (2), 134-141.
Englund, S. , Kierkegaard, M. , Burman, J. , Fink, K. , Fogdell-Hahn, A. , Gunnarsson, M. , Hillert, J. , Langer-Gould, A. & et al. (2023). Predictors of patient-reported fatigue symptom severity in a nationwide multiple sclerosis cohort. Multiple Sclerosis and Related Disorders, 70.
Jons, D. , Zetterberg, H. , Biström, M. , Alonso-Magdalena, L. , Gunnarsson, M. , Vrethem, M. , Blennow, K. , Nilsson, S. & et al. (2022). Axonal injury in asymptomatic individuals preceding onset of multiple sclerosis. Annals of Clinical and Translational Neurology, 9 (6), 882-887.
Longinetti, E. , Bower, H. , McKay, K. A. , Englund, S. , Burman, J. , Fink, K. , Fogdell-Hahn, A. , Gunnarsson, M. & et al. (2022). COVID-19 clinical outcomes and DMT of MS patients and population-based controls. Annals of Clinical and Translational Neurology, 9 (9), 1449-1458.
Tedeholm, H. , Piehl, F. , Lycke, J. , Link, J. , Stawiarz, L. , Burman, J. , de Flon, P. , Fink, K. & et al. (2022). Effectiveness of first generation disease-modifying therapy to prevent conversion to secondary progressive multiple sclerosis.. Multiple Sclerosis and Related Disorders, 68.
Grut, V. , Biström, M. , Salzer, J. , Stridh, P. , Lindam, A. , Alonso-Magdalena, L. , Andersen, O. , Jons, D. & et al. (2022). Free Vitamin D₃ Index and Vitamin D-binding protein in multiple sclerosis: a presymptomatic case-control study. European Journal of Neurology, 29 (8), 2335-2342.
Svenningsson, A. , Frisell, T. , Burman, J. , Salzer, J. , Fink, K. , Hallberg, S. , Hambraeus, J. , Axelsson, M. & et al. (2022). Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial. Lancet Neurology, 21 (8), 693-703.
Grut, V. , Biström, M. , Salzer, J. , Stridh, P. , Lindam, A. , Alonso-Magdalena, L. , Andersen, O. , Jons, D. & et al. (2022). Systemic inflammation and risk of multiple sclerosis: A presymptomatic case-control study. Multiple Sclerosis Journal, Experimental, Translational and Clinical, 8 (4).
Grut, V. , Biström, M. , Salzer, J. , Stridh, P. , Jons, D. , Gustafsson, R. , Fogdell-Hahn, A. , Huang, J. & et al. (2021). Cytomegalovirus seropositivity is associated with reduced risk of multiple sclerosis: a presymptomatic case-control study. European Journal of Neurology, 28 (9), 3072-3079.
Biström, M. , Jons, D. , Engdahl, E. , Gustafsson, R. , Huang, J. , Brenner, N. , Butt, J. , Alonso-Magdalena, L. & et al. (2021). Epstein-Barr virus infection after adolescence and Human herpesvirus 6A as risk factors for multiple sclerosis. European Journal of Neurology, 28 (2), 579-586.
Biström, M. , Hultdin, J. , Andersen, O. , Alonso-Magdalena, L. , Jons, D. , Gunnarsson, M. , Vrethem, M. & Sundström, P. (2021). Leptin levels are associated with multiple sclerosis risk. Multiple Sclerosis Journal, 27 (1), 19-27.
Petersson, M. , Feresiadou, A. , Jons, D. , Ilinca, A. , Lundin, F. , Johansson, R. , Budzianowska, A. , Roos, A. & et al. (2021). Patient-Reported Symptom Severity in a Nationwide Myasthenia Gravis Cohort: Cross-sectional Analysis of the Swedish GEMG Study. Neurology, 97 (14), E1382-E1391.
Westerdahl, E. , Gunnarsson, M. , Wittrin, A. & Nilsagård, Y. (2021). Pulmonary Function and Respiratory Muscle Strength in Patients with Multiple Sclerosis. Multiple Sclerosis International, 2021.
Alping, P. , Askling, J. , Burman, J. , Fink, K. , Fogdell-Hahn, A. , Gunnarsson, M. , Hillert, J. , Langer-Gould, A. & et al. (2020). Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients. Annals of Neurology, 87 (5), 688-699.
Granqvist, M. , Burman, J. , Gunnarsson, M. , Lycke, J. , Nilsson, P. , Olsson, T. , Sundström, P. , Svenningsson, A. & et al. (2020). Comparative effectiveness of dimethyl fumarate as the initial and secondary treatment for MS. Multiple Sclerosis Journal, 26 (12), 1532-1539.
Luna, G. , Alping, P. , Burman, J. , Fink, K. , Fogdell-Hahn, A. , Gunnarsson, M. , Hillert, J. , Langer-Gould, A. & et al. (2020). Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. JAMA Neurology, 77 (2), 184-191.
de Flon, P. , Laurell, K. , Sundström, P. , Blennow, K. , Söderström, L. , Zetterberg, H. , Gunnarsson, M. & Svenningsson, A. (2019). Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial. Acta Neurologica Scandinavica, 139 (5), 462-468.
Alping, P. , Piehl, F. , Langer-Gould, A. , Frisell, T. , Burman, J. , Fink, K. , Fogdell-Hahn, A. , Gunnarsson, M. & et al. (2019). Validation of the Swedish Multiple Sclerosis Register Further Improving a Resource for Pharmacoepidemiologic Evaluations. Epidemiology, 30 (2), 230-233.
Krauss, W. , Gunnarsson, M. , Nilsson, M. & Thunberg, P. (2018). Conventional and synthetic MRI in multiple sclerosis: a comparative study. European Radiology, 28 (4), 1692-1700.
de Flon, P. , Söderström, L. , Laurell, K. , Dring, A. , Sundström, P. , Gunnarsson, M. & Svenningsson, A. (2018). Immunological profile in cerebrospinal fluid of patients with multiple sclerosis after treatment switch to rituximab and compared with healthy controls. PLOS ONE, 13 (2).
Carling, A. , Forsberg, A. , Gunnarsson, M. & Nilsagård, Y. (2017). CoDuSe group exercise programme improves balance and reduces falls in people with multiple sclerosis: A multi-centre, randomized, controlled pilot study. Multiple Sclerosis Journal, 23 (10), 1394-1404.
de Flon, P. , Laurell, K. , Söderström, L. , Gunnarsson, M. & Svenningsson, A. (2017). Improved treatment satisfaction after switching therapy to rituximab in relapsing-remitting MS. Multiple Sclerosis Journal, 23 (9), 1249-1257.
Novakova, L. , Zetterberg, H. , Sundström, P. , Axelsson, M. , Khademi, M. , Gunnarsson, M. , Malmeström, C. , Svenningsson, A. & et al. (2017). Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology, 89 (22), 2230-2237.
de Flon, P. , Söderström, L. , Laurell, K. , Gunnarsson, M. & Svenningsson, A. (2016). Changes of cerebrospinal fluid cytokine profile as a result of switching from first line MS-therapies to rituximab. Multiple Sclerosis Journal, 22 (Suppl. 3), 622-622.
Westerdahl, E. , Wittrin, A. , Kånåhols, M. , Gunnarsson, M. & Nilsagård, Y. (2016). Deep breathing exercises with positive expiratory pressure in patients with multiple sclerosis: a randomized controlled trial. Clinical Respiratory Journal, 10 (6), 698-706.
de Flon, P. , Gunnarsson, M. , Laurell, K. , Söderström, L. , Birgander, R. , Lindqvist, T. , Krauss, W. , Dring, A. & et al. (2016). Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab. Neurology, 87 (2), 141-147.
Nilsagård, Y. , Westerdahl, E. , Wittrin, A. & Gunnarsson, M. (2016). Walking Distance as a Predictor of Falls in People With Multiple Sclerosis. Physiotherapy Research International, 21 (2), 102-108.
Krauss, W. , Gunnarsson, M. , Andersson, T. & Thunberg, P. (2015). Accuracy and reproducibility of a quantitative magnetic resonance imaging method for concurrent measurements of tissue relaxation times and proton density. Magnetic Resonance Imaging, 33 (5), 584-591.
Gunnarsson, M. , Udumyan, R. , Bahmanyar, S. , Nilsagård, Y. & Montgomery, S. (2015). Characteristics in childhood and adolescence associated with future multiple sclerosis risk in men: cohort study. European Journal of Neurology, 22 (7), 1131-1137.
Burman, J. , Iacobaeus, E. , Svenningsson, A. , Lycke, J. , Gunnarsson, M. , Nilsson, P. , Vrethem, M. , Fredrikson, S. & et al. (2014). Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. Journal of Neurology, Neurosurgery and Psychiatry, 85 (10), 1116-1121.
Axelsson, M. , Malmeström, C. , Gunnarsson, M. , Zetterberg, H. , Sundstrom, P. , Lycke, J. & Svenningsson, A. (2014). Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. Multiple Sclerosis Journal, 20 (1), 43-50.

Artiklar, forskningsöversikter

Bridel, C. , Gunnarsson, M. & Weiss, E. J. (2019). Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. JAMA Neurology, 76 (9), 1035-1048.
Vågberg, M. , Axelsson, M. , Birgander, R. , Burman, J. , Cananau, C. , Forslin, Y. , Granberg, T. , Gunnarsson, M. & et al. (2017). Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society. Acta Neurologica Scandinavica, 135 (1), 17-24.

Konferensbidrag

Forsberg, L. , Larsson, V. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. , Lycke, J. , Landtblom, A. & et al. (2023). A comparison of administration and discontinuation of Natalizuamb in Sweden over time for patients treated with either sucutaneous (SC) or intravenous (IV) administration methods since July 2021. I: Multiple Sclerosis Journal. Konferensbidrag vid 9th Joint ECTRIMS-ACTRIMS meeting, Milan, Italy, October 11-13, 2023. (ss. 617-617). Sage Publications.
Larsson, V. , Nilsson, P. , Magdalena, L. A. , Svenningsson, A. , Gunnarsson, M. , Ayad, A. , Vrethem, M. , Burman, J. & et al. (2023). CLADCOMS- CLADribine tablets long-term Control Of MS - a post-marketing investigator driven study. I: Multiple Sclerosis Journal. Konferensbidrag vid 9th Joint ECTRIMS-ACTRIMS meeting, Milan, Italy, October 11-13, 2023. (ss. 968-969). Sage Publications.
Larsson, V. , Forsberg, L. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. , Lycke, J. , Landtblom, A. & et al. (2023). Clinical Effectiveness and Safety of Cladribine Tablets for Patients Treated at least 24 Months in the Swedish post-market surveillance study "Immunomodulation and Multiple Sclerosis Epidemiology 10"(IMSE 10). I: Multiple Sclerosis Journal. Konferensbidrag vid 9th Joint ECTRIMS-ACTRIMS meeting, Milan, Italy, October 11-13, 2023. (ss. 616-616). Sage Publications.
Jons, D. , Grut, V. , Bergström, T. , Zetterberg, H. , Bistrom, M. , Gunnarsson, M. , Vrethem, M. , Brenner, N. & et al. (2023). Epstein-Barr virus seroreactivity, putative autoimmunity and axonal injury in pre-symptomatic multiple sclerosis. I: Multiple Sclerosis Journal. Konferensbidrag vid 9th Joint ECTRIMS-ACTRIMS meeting, Milan, Italy, October 11-13, 2023. (ss. 39-40). Sage Publications.
Forsberg, L. , Larsson, V. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. , Lycke, J. , Landtblom, A. & et al. (2023). Improved clinical outcomes in patients treated with Natalizumab for at least 11 years - Real-world data from a Swedish national post-marketing surveillance study (IMSE 1). I: Multiple Sclerosis Journal. Konferensbidrag vid 9th Joint ECTRIMS-ACTRIMS meeting, Milan, Italy, October 11-13, 2023. (ss. 965-966). Sage Publications.
Petersson, M. , Jons, D. , Feresiadou, A. , Ilinca, A. , Lundin, F. , Johansson, R. , Budzianowska, A. , Roos, A. & et al. (2023). Smoking and alcohol associated to the risk of developing Myasthenia gravis in a Swedish nationwide prevalent cohort. I: European Journal of Neurology. Konferensbidrag vid 9th Congress of the European Academy of Neurology, Budapest, Hungary, July 1-4, 2023. (ss. 54-55). John Wiley & Sons.
Fink, K. , Nilsson, P. , Alonso, L. , Sveningsson, A. , Gunnarsson, M. , Lange, N. , Ayad, A. , Vrethem, M. & et al. (2022). CLADCOMS - CLADribine tablets long-term Control Of MS - a post-marketing investigator driven study. I: Multiple Sclerosis Journal. Konferensbidrag vid 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2022), Amsterdam, the Netherlands, October 26-28, 2022. (ss. 847-848). Sage Publications.
Rosengren, V. , Forsberg, L. , Ekström, E. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. , Lycke, J. & et al. (2022). Clinical effectiveness and safety of cladribine tablets for patients treated at least 12 months in the Swedish post-market surveillance study "immunomodulation and multiple sclerosis epidemiology 10" (IMSE 10). I: Multiple Sclerosis Journal. Konferensbidrag vid 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2022), Amsterdam, the Netherlands, October 26-28, 2022. (ss. 638-639). Sage Publications.
Forsberg, L. , Ekström, E. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. , Lycke, J. , Lantblom, A. -. & et al. (2022). Clinical effectiveness and safety of dimethyl fumarate for patients treated at least 6 years in the swedish post-market surveillance study "immunomodulation and multiple sclerosis epidemiology 5" (IMSE 5). I: Multiple Sclerosis Journal. Konferensbidrag vid 38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Netherlands, October 26-28, 2022. (ss. 858-859). Sage Publications.
Forsberg, L. , Ekström, E. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. , Lycke, J. , Landtblom, A. -. & et al. (2022). Improved clinical outcomes in patients treated with natalizumab for at least 11 years - real-world data from a swedish national post-marketing surveillance study (IMSE 1). I: Multiple Sclerosis Journal. Konferensbidrag vid 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2022), Amsterdam, the Netherlands, October 26-28, 2022. (ss. 352-353). Sage Publications.
Jons, D. , Bergström, T. , Zetterberg, H. , Biström, M. , Alonso-Magdalena, L. , Gunnarsson, M. , Vrethem, M. , Blennow, K. & et al. (2022). Increase in Epstein Barr virus serologies precedes neuroaxonal damage in pre-symptomatic multiple sclerosis. I: Multiple Sclerosis Journal. Konferensbidrag vid 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2022), Amsterdam, the Netherlands, October 26-28, 2022 . (ss. 86-87). Sage Publications.
Longinetti, E. , Högelin, K. A. , Kockum, I. , Englund, S. , Burman, J. , Fink, K. , Fogdell-Hahn, A. , Gunnarsson, M. & et al. (2022). SARS-COV2 exposure rates and serological response of people living with MS. I: Multiple Sclerosis Journal. Konferensbidrag vid 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2022), Amsterdam, the Netherlands, October 26-28, 2022. (ss. 515-516). Sage Publications.
Ekström, E. , Rosengren, V. , Kågström, S. , Forsberg, L. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. & et al. (2021). A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of alemtuzumab (IMSE 3). I: Multiple Sclerosis Journal. Konferensbidrag vid 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2021), The Digital Experience, October 13-15 2021. (ss. 616-617). Sage Publications.
Rosengren, V. , Ekström, E. , Forsberg, L. , Kågström, S. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. & et al. (2021). Clinical effectiveness and safety of cladribine tablets for patients treated at least 12 months in the swedish post-market surveillance study "immunomodulation and multiple sclerosis epidemiology 10" (IMSE 10). I: Multiple Sclerosis Journal. Konferensbidrag vid 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2021), The Digital Experience, October 13-15 2021. (ss. 623-624). Sage Publications.
Rosengren, V. , Ekström, E. , Forsberg, L. , Kågström, S. , Berglund, A. , Hillert, J. , Nilsson, P. , Dahle, C. & et al. (2021). Clinical effectiveness and safety of dimethyl fumarate for patients treated at least 5 years in the Swedish post-market surveillance study "Immunomodulation and Multiple Sclerosis Epidemiology 5" (IMSE 5). I: Multiple Sclerosis Journal. Konferensbidrag vid 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2021), The Digital Experience, October 13-15 2021. (ss. 615-616). Sage Publications.
Rosengren, V. , Ekström, E. , Forsberg, L. , Kågström, S. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. & et al. (2021). Clinical effectiveness and safety of teriflunomide for patients treated at least 48 months in the Swedish post-market surveillance study "Immunomodulation and Multiple Sclerosis Epidemiology 4" (IMSE 4). I: Multiple Sclerosis Journal. Konferensbidrag vid 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2021), The Digital Experience, October 13-15 2021. (ss. 612-613). Sage Publications.
Alping, P. , Burman, J. , Fink, K. , Fogdell-Hahn, A. , Gunnarsson, M. , Hillert, J. , Langer-Gould, A. , Lycke, J. & et al. (2021). Effectiveness of initial MS treatments in the COMBAT-MS trial: injectables, dimethyl fumarate, natalizumab and rituximab. I: Multiple Sclerosis Journal. Konferensbidrag vid 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2021), The Digital Experience, October 13-15 2021. (ss. 21-22). Sage Publications.
Ekström, E. , Rosengren, V. , Kågström, S. , Forsberg, L. , Berglund, A. , Hillert, J. , Nilsson, P. , Dahle, C. & et al. (2021). Real-world longitudinal data of peginterferon beta-1a from the Swedish national post-marketing surveillance study (IMSE 6) - effectiveness and safety profile. I: Multiple Sclerosis Journal. Konferensbidrag vid 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2021), The Digital Experience, October 13-15 2021. (ss. 626-627). Sage Publications.
Ekström, E. , Rosengren, V. , Kågström, S. , Forsberg, L. , Berglund, A. , Hillert, J. , Nilsson, P. , Dahle, C. & et al. (2021). The long-term safety and effectiveness of natalizumab (IMSE 1) - Real-world data from a Swedish nationwide pharmaco-epidemiological study. I: Multiple Sclerosis Journal. Konferensbidrag vid 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2021), The Digital Experience, October 13-15 2021. (ss. 618-619). Sage Publications.
Longinetti, E. , Englund, S. , Burman, J. , Fogdell-Hahn, A. , Gunnarsson, M. , Hillert, J. , Langer-Gould, A. , Lycke, J. & et al. (2021). Trajectories of processing speed, disability, and their connections, over the years following disease modulatory treatment initiation among relapsing-remitting multiple sclerosis patients. I: Multiple Sclerosis Journal. Konferensbidrag vid 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2021), The Digital Experience, October 13-15 2021. (ss. 677-678). Sage Publications.
Forsberg, L. , Kågström, S. , Leandersson, Å. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. , Lycke, J. & et al. (2020). A swedish post-market surveillance study: long-term effectiveness and safety of cladribine tablets (IMSE 10) for patients treated at least 12 months. I: Multiple Sclerosis Journal. Konferensbidrag vid 8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual), September 11-13, 2020. (ss. 254-254). Sage Publications.
Forsberg, L. , Kågström, S. , Leandersson, Å. , Berglund, A. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. & et al. (2020). A swedish post-market surveillance study: long-term effectiveness and safety of dimethyl fumarate (imse 5) for patients treated at least 36 months: on-demand eposters p0001-p0286. I: Multiple Sclerosis Journal. Konferensbidrag vid 8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual), September 11-13, 2020. (ss. 254-255). Sage Publications.
Leandersson, Å. , Kågström, S. , Forsberg, L. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. , Lycke, J. & et al. (2020). A swedish post-market surveillance study of the long-term effectiveness and safety of alemtuzumab (imse 3) for patients treated for at least 36 months. I: Multiple Sclerosis Journal. Konferensbidrag vid 8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual), September 11-13, 2020. (ss. 252-253). Sage Publications.
Forsberg, L. , Kågström, S. , Leandersson, Å. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. , Lycke, J. & et al. (2020). A swedish post-market surveillance study of the long-term effectiveness and safety of teriflunomid (IMSE 4) for patients treated at least 36 months. I: Multiple Sclerosis Journal. Konferensbidrag vid 8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual), September 11-13, 2020. (ss. 253-254). Sage Publications.
Kågström, S. , Leandersson, Å. , Forsberg, L. , Berglund, A. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. & et al. (2020). Efficacy and safety in patients treated with natalizumab for at least 10 years - real-world data from a swedish national surveillance study (IMSE 1). I: Multiple Sclerosis Journal. Konferensbidrag vid 8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual), September 11-13, 2020. (ss. 279-280). Sage Publications.
Kågström, S. , Leandersson, Å. , Forsberg, L. , Berglund, A. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. & et al. (2020). Real-world data of peginterferon beta-1a from a swedish national post-marketing surveillance study (IMSE 6) - effectiveness and safety profile. I: Multiple Sclerosis Journal. Konferensbidrag vid 8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual), September 11-13, 2020. (ss. 302-302). Sage Publications.
Leandersson, Å. , Kågström, S. , Forsberg, L. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. , Lycke, J. & et al. (2020). Relation of edss to patient-reported outcome measurements in ms: real-world data from a swedish nationwide study of fingolimod (imse 2). I: Multiple Sclerosis Journal. Konferensbidrag vid 8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual), September 11-13, 2020. (ss. 187-188). Sage Publications.
Forsberg, L. , Kågström, S. , Fält, A. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. , Lycke, J. & et al. (2019). A Swedish Nationwide study of the long-term effectiveness and safety of teriflunomid based on data from the Swedish "Immunomodulation and Multiple Sclerosis Epidemiology" Study (IMSE 4). I: Multiple Sclerosis Journal. Konferensbidrag vid 35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS 2019) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, September 11-13, 2019. (ss. 316-316). Sage Publications.
Fält, A. , Kågström, S. , Forsberg, L. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. , Lycke, J. & et al. (2019). A swedish post-market surveillance study of the long-term effectiveness and safety of alemtuzumab (IMSE 3) for patients treated at least 24 months. I: Multiple Sclerosis Journal. Konferensbidrag vid 35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS 2019) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, September 11-13, 2019. (ss. 327-328). Sage Publications.
Fält, A. , Kågström, S. , Forsberg, L. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. , Lycke, J. & et al. (2019). A Swedish real word study of the long-term effectiveness and safety of fingolimod (IMSE 2) with focus on patients treated at least 48 months. I: Multiple Sclerosis Journal. Konferensbidrag vid 35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS 2019) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, September 11-13, 2019. (ss. 536-537). Sage Publications.
Forsberg, L. , Kågström, S. , Fält, A. , Berglund, A. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. & et al. (2019). Clinical effectiveness of dimethyl fumarate with focus on patients treated at least 36 months - a Swedish nationwide study of the long-term effectiveness and safety of dimethyl fumarate (IMSE5). I: Multiple Sclerosis Journal. Konferensbidrag vid 35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS 2019) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, September 11-13, 2019. (ss. 316-317). Sage Publications.
Kågström, S. , Fält, A. , Forsberg, L. , Berglund, A. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. & et al. (2019). Improved clinical outcomes in patients treated with natalizumab for at least 8 years - real-world data from a Swedish national post-marketing surveillance study (IMSE 1). I: Multiple Sclerosis Journal. Konferensbidrag vid 35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS 2019) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, September 11-13, 2019. (ss. 763-764). Sage Publications.
Biström, M. , Hultdin, J. , Andersen, O. , Alonso-Magdalena, L. , Jons, D. , Gunnarsson, M. , Vrethem, M. & Sundström, P. (2019). Leptin levels are associated with multiple sclerosis risk. I: Multiple Sclerosis Journal. Konferensbidrag vid 35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS 2019) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, September 11-13, 2019. (ss. 904-904). Sage Publications.
Demirbüker, S. S. , Kågström, S. , Fält, A. , Berglund, A. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. & et al. (2018). A Swedish nationwide pharmaco-epidemiological and genetic study of the long-term safety and effectiveness of dimethyl fumarate (IMSE 5). I: Multiple Sclerosis Journal. Konferensbidrag vid 34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin, Germany, October 10-12, 2018. (ss. 701-702). Sage Publications.
Kågström, S. , Fält, A. , Demirbüker, S. S. , Berglund, A. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. & et al. (2018). A Swedish nationwide pharmaco-epidemiological and genetic study of the long-term safety and effectiveness of natalizumab (IMSE 1). I: Multiple Sclerosis Journal. Konferensbidrag vid 34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin, Germany, October 10-12, 2018. (ss. 699-700). Sage Publications.
Fält, A. , Kågström, S. , Demirbuker, S. S. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. , Lycke, J. & et al. (2018). A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of alemtuzumab (IMSE 3). I: Multiple Sclerosis Journal. Konferensbidrag vid 34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin, Germany, October 10-12, 2018. (ss. 706-707). Sage Publications.
Fält, A. , Kågström, S. , Demirbüker, S. S. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. , Lycke, J. & et al. (2018). A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of fingolimod (IMSE 2). I: Multiple Sclerosis Journal. Konferensbidrag vid 34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin, Germany, October 10-12, 2018. (ss. 696-697). Sage Publications.
Demirbüker, S. S. , Kågström, S. , Fält, A. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. , Lycke, J. & et al. (2018). A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of teriflunomid (IMSE 4). I: Multiple Sclerosis Journal. Konferensbidrag vid 34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin, Germany, October 10-12, 2018. (ss. 922-923). Sage Publications.
Biström, M. , Andersen, O. , Alonso-Magdalena, L. , Gunnarsson, M. , Vrethem, M. , Hultdin, J. & Sundström, P. (2018). High serum concentrations of vitamin D may protect against multiple sclerosis. I: Multiple Sclerosis Journal. Konferensbidrag vid 34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin, Germany, October 10-12, 2018. (ss. 1001-1002). Sage Publications.
Kågström, S. , Fält, A. , Demirbuker, S. S. , Berglund, A. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. & et al. (2018). Real-world longitudinal data of peginterferon beta-1a from a Swedish national post-marketing surveillance study (IMSE 6) - efficacy and safety profile. I: Multiple Sclerosis Journal. Konferensbidrag vid 34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin, Germany, October 10-12, 2018. (ss. 927-928). Sage Publications.
Novakova, L. , Zetterberg, H. , Axelsson, M. , Sundström, P. , Khademi, M. , Gunnarsson, M. , Malmeström, C. , Svenningsson, A. & et al. (2017). Neurofilament light in serum for monitoring multiple sclerosis: A new quantitative tool for measuring disease activity and therapeutic response. I: European Journal of Neurology. Konferensbidrag vid 3rd Congress of the European-Academy-of-Neurology, Amsterdam, Netherlands, June, 2017. (ss. 577-577). John Wiley & Sons.
Westerdahl, E. , Wittrin, A. , Kånåhols, M. , Gunnarsson, M. & Nilsagård, Y. (2015). Breathing exercises for patient with multiple sclerosis. Konferensbidrag vid Fysioterapi 2015, Stockholm Waterfront Congress Centre, Stockholm, 21-23 okt, 2015.
Westerdahl, E. , Wittrin, A. , Kånåhols, M. , Gunnarsson, M. & Nilsagård, Y. (2015). Breathing exercises for patients with multiple sclerosis: a randomized controlled trial. I: Physiotherapy. Konferensbidrag vid WCPT (World Confederation for physical therapy) Congress, Singapore, 1-4 May, 2015. Elsevier.
Westerdahl, E. , Wittrin, A. , Kånåhols, M. , Gunnarsson, M. & Nilsagård, Y. (2014). Breathing exercises for patients with multiple sclerosis: a randomized controlled trial. I: European Respiratory Journal. Konferensbidrag vid ERS (European Respiratory Society) Annual Congress, Munchen, Germany, 6-10 Sept, 2014. European Respiratory Society.
Nilsagård, Y. , Westerdahl, E. , Wittrin, A. & Gunnarsson, M. (2014). Correlation between maximal walking distance and self-rated limitations in walking. I: Multiple Sclerosis Journal. Konferensbidrag vid 19th Annual Conference on Rehabilitation in Multiple Sclerosis (RIMS), JUN 06-07, 2014, Brighton, ENGLAND. (ss. 992-992). Sage Publications.
Wittrin, A. , Nilsagård, Y. , Westerdahl, E. & Gunnarsson, M. (2013). Self-assessment of walking ability in patients with multiple sclerosis and its impact on the expanded disability status scale (EDSS) score. I: Multiple Sclerosis Journal. Konferensbidrag vid 29th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis / 18th Annual Conference of Rehabilitation in MS, OCT 02-05, 2013, Copenhagen, DENMARK. (ss. 118-118). Sage Publications.